Schering Corporation

Merck Sharp + Dohme Corp.

Pharmacopeia Inc.

Schering Coporation

Jagdish A Desai

Alan B Cooper

James J-s Wang

Ronald J Doll

Hugh Y Zhu

Viyyoor Moopil Girijavallabhan

Joseph Michael Kelly

Gerald Wayne Shipps, Jr

Dinanath F Rane

Yongqi Deng

Neng-Yang Shih

Timothy J Guzi

Xiaolei Gao

Carmen S Alvarez

Sobhana Babu Boga

Liang Zhu

Yang Nan

Abdul-Basit Alhassan

F George Njoroge

Arthur G Taveras

Anil K Saksena

Vincent Stewart Madison

M Arshad Siddiqui

Sunil Paliwal

Alan W Hruza

Li Xiao

Hon-Chung Tsui

Jianping Chao

Robert Sun

Tarik Lalwani

Ahmed Abdi Samatar

Cynthia J Aki

Tong Wang

Johan A Ferreira

Youhao Dong

John J Baldwin

Ge Li

Alan K Mallams

Adriano Afonso

Raymond G Lovey

Huw M Nash

Patrick A Pinto

Russell E Pike

Jay Weinstein

Kartik M Keertikar

Ray Anthony James

Bancha Vibulbhan

Chia-Yu Huang

Mehul F Patel

Patrick J Curran

Keith P Minor

Bama Santhanam

Sie-Mun Lo

Azim Alan Celebi

D Allen Annis

Xin Yao

Subrahmanyam Gudipati

Yiji Wu

James J-S Wang

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring) cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1). 

Compounds that are ERK inhibitors

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0. 

Disclosed are the ERK inhibitors of formula 1.0: (Formula (A1)), and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine ring that can have a bridge or a fused ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula A1. 

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substituents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Disclosed are novel tricyclic compounds of the formula: and a pharmaceutically acceptable salts or solvates thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are uses of the compounds of formula (I) for the manufacture of a medicament for the treatment of cancer.

Farnesyl protein transferase inhibitors as antitumor agents

The present invention provides compounds of formula I wherein X, Y, R-Rare as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided. 

Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents

Disclosed are novel tricyclic compounds represented by the formula (1.0): and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Farnesyl protein transferase inhibitors

Compounds useful for inhibition of farnesyl protein transferase

Novel tricyclic N-cyanoimine compounds and pharmaceutical compositions of formula (1.0) ##STR1## or a pharmaceutically acceptable salt or solvate thereof, wherein a, b, c, d, R.sup.1 -R.sup.8, X and Z are defined herein. Such compounds are inhibitors of the enzyme, farnesyl protein transferase. The compounds are useful for inhibiting Ras function and therefore inhibiting the abnormal growth of cells, in a mammals such as a human.

Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein

2-Azolylmethyl-3-difluorobenzyloxy-2,3-dihydro-5- and 6-fluorobenzo[b]thiophen antifungally compounds, especially 2-(1H-imidazolylmethyl-3-(2',6'-difluorobenzyloxy)-2,3-dihydro-5-fluoroben zo[b]thiophene, pharmaceutical compositions containing them and their use in treating fungal infections in animals including humans are disclosed.

Antifungal 2-azolylmethyl-3-difluorobenzyloxy-2,3-dihydrofluoro-benzo(B)

Growing community of inventors

Monroe Township, NJ, United States of America

Jagdish A Desai